,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['destiny-breast03', 'breast']
amazing #asco22 safety follow-up of the randomized, phase 3 study destiny-breast03 #oncoalert 
Associate Professor, Florence University, Italy. Clinical Oncologist with focus on breast, radiation, research. Opinions are my own. RT not endorsement.